Standard operating procedure

Similar documents
Standard operating procedure

Guidance for applicants requesting scientific advice

Guidance for the conduct of good clinical practice inspections

Delivery time frame for the EU portal and EU database

Questions and answers on the procedure of PIP compliance verification at EMA, and on paediatric rewards

CMDv/BPG/002. BEST PRACTICE GUIDE for Veterinary Decentralised Procedure (DCP)

European Medicines Agency guidance for applicants seeking scientific advice and protocol assistance

Procedure for handling applications for authorisation and review reports under REACH

NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE

General FAQ relating to e-submission for Veterinary Applications

Assessment of patient, consumer and healthcare professional organisations compliance with EMA eligibility criteria

EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL. Safety of the food chain Chemicals, contaminants, pesticides

Adopted by Pharmacovigilance Risk Assessment Committee 20 February Adopted by Pharmacovigilance Inspectors Working Group 21 March 2014

A Dedicated Post Authorisation Measure Submission Form

Guidance on the preparation of dossiers for harmonised classification and labelling (CLH) under Regulation (EC) No.

SPECIFIC PRIVACY STATEMENT ERCEA ERC- Proposals Evaluation, Grants Management and Follow-up

Work plan for GCP Inspectors Working Group for 2018

Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol

Scientific Advice and Protocol Assistance at the EMEA

BEST PRACTICE GUIDE FOR DECENTRALISED AND MUTUAL RECOGNITION PROCEDURES

Recommendation on duplicate applications in mutual recognition and decentralised procedures

CALL FOR EXPRESSION OF INTEREST. Seconded National Experts for the ERCEA ERCEA/SNE/143/2017

Commission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics Oslo

CALL FOR EXPRESSION OF INTEREST. Seconded National Experts for the ERCEA ERCEA/SNE/143/2017

European network of paediatric research (Enpr-EMA)

Brussels, 12 June 2014 COUNCIL OF THE EUROPEAN UNION 10855/14. Interinstitutional File: 2012/0266 (COD) 2012/0267 (COD)

Clinical data Publication Webinar

Patient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force

Questions and answers about Recycling Processes

DRAFT OPINION. EN United in diversity EN. European Parliament 2018/0018(COD) of the Committee on Industry, Research and Energy

European network of paediatric research (EnprEMA)

BASG / Austrian Medicines and Medical Devices Agency Institute Assessment & Analytics Traisengasse 5, A-1200 Vienna

European network of paediatric research (EnprEMA)

Topical Peer Review 2017 Ageing Management of Nuclear Power Plants

Remediation, Resolution and Outcomes

Guideline on good pharmacovigilance practices (GVP)

R. Fay, Research Governance & GCP Manager K. Mahiouz, Clinical Trials Facilitator E. Clough, R&D Governance Operations Manager

EUROPEAN PARLIAMENT Committee on the Environment, Public Health and Food Safety

EDQM roadmap for electronic submissions

Unofficial copy not valid

ECHA and the implementation of REACH,CLP and other tasks

EV Reporting process for users: Creating and sending ICSRs using EVWEB part II

- Proposal for a Regulation on HTA- DG SANTE - Health Systems and Products Medical Products: safety, quality, innovation

Transmission to CHMP December Adoption by CHMP for release for consultation December 2008

Article 29(1) Referral

UNITAID PROPOSAL PROCESS

European Medicines Agency Inspections ANNEX V TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: PHASE I UNITS

DECISION 15/2009/GB OF THE GOVERNING BOARD OF THE EUROPEAN POLICE COLLEGE AMENDING DECISION 30/2006/GB OF THE GOVERNING BOARD

Guideline on good pharmacovigilance practices (GVP)

REACH Evaluation. Graham Lloyd Regulatory/Technical. REACH in Practice Conference 1 June, Steptoe & Johnson LLP & Regulatory Compliance Ltd

EUROPEAN COMMISSION DIRECTORATE-GENERAL JUSTICE

Reconfirmation_SOP. - If the letter states that they were. Description/ Scope:

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

1 The EU Harmonised technical ectd guidance version 4.0

Document Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026

Update on FDA-EMA QbD Pilot

ICH Topic Q4B Annex 6 Uniformity of Dosage Units General Chapter. Step 3

Patient Registries Initiative Background, Achievements, Next steps

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

CONTRACT SPECIFICATION

Guideline for Research Programmes Rules for the establishment and implementation of programmes falling under the Programme Area Research

COMMISSION IMPLEMENTING REGULATION (EU)

esubmission roadmap v2.0: Industry viewpoint

Annex 2 to the HMA esubmission Roadmap: Implementation of mandatory use of ectd format for regulatory submissions

- Proposal for a Regulation on HTA- Ioana Siska, MD, PhD DG SANTE - Health Systems and Products Medical Products: safety, quality, innovation

SOP16: Standard Operating Procedure for Establishing Sites and Centres - Site Setup

Use of disease registries for benefitrisk evaluation of medicines: A regulatory perspective. DIA Europe April Basel, Switzerland

EMA Patients and Consumers Annual Training Overview:

DRAFT AGENDA FOR THE MEETING OF THE STANDING COMMITTEE AND OF THE WORKING GROUP PLANT PROTECTION PRODUCTS - LEGISLATION 13 February 2004

HERCULE III PROGRAMME CALL FOR PROPOSALS REF. Hercule III 2014 ANTI-FRAUD TRAINING E PROGRA MME ANTI-FRAU

Guidance Notes for preparing the Grant Agreement

4. Multi Stakeholder: Late & Early Dialogue

This policy applies to all staff and contractors working for the Agency and all persons working within its demised premises.

Research Governance Framework 2 nd Edition, Medicine for Human Use (Clinical Trial) Regulations 2004

NIHR Research for Patient Benefit (RfPB) Application Process

CALL FOR PROPOSALS FOR PARTNERSHIP1 COMM/FPA/2016

Education and Training Committee, 5 June 2014

CLP the implementation of GHS in the EU Facts and practical advice

Open call for proposals VP/2004/021. Initiatives to promote gender equality between women and men, including activities concerning migrant women

Document Title: Investigator Site File. Document Number: 019

PHARMACY, MEDICINES & POISONS BOARD GUIDELINES FOR REVIEW/EVALUATION CLINICAL TRIAL APPLICATIONS FOR VACCINES AND BIOLOGICALS MALAWI

ASSESSMENT OF THE CONSOLIDATED ANNUAL ACTIVITY REPORT OF THE AUTHORISING OFFICER FOR THE YEAR 2014

GENERAL TENDER CONDITIONS

Guidance on the Biocidal Products Regulation

Electric Mobility Europe Call 2016

Submission of a clinical trial for access to ECRIN services Notice to the Applicant

CHEMICALS (Classification, Labelling, Packaging of substances and mixtures -CLP) Screening Meeting EU Serbia June 2013

Compassionate Use Systems in the EU How to improve for early access to patients

AUDIT REPORT. Audit of Offi cial Controls in Local Authority Supervised Establishments Cork County Council

ICT, FET Open LIFT ICT-FP Using Local Inference in Massively Distributed Systems Collaborative Project D 7.1 Quality Assurance Plan

1. Applications must contain the following information (Article 33 of Regulation)

ERN Assessment Manual for Applicants 2. Technical Toolbox for Applicants

Public Diplomacy, Policy Research and Outreach Devoted to the European Union and EU-Canada Relations

Guidelines for new FOCAL POINTS

COUNTY OFFICIAL PLAN AMENDMENT PROCESS (TYPICAL)

European Aviation Safety Agency Doc # Approval Date PR.CAP Name Validation Date. Verified by: Ralf ERCKMANN Validated 24/06/2015

Scientific and Regulatory Advice by the Federal Institute for Drugs and Medical Devices (BfArM) Guidance for Applicants (Revision 9 1 )

***I DRAFT REPORT. EN United in diversity EN. European Parliament 2018/0018(COD)

New European Union Clinical Trial Regulations

Annual report of the Good Clinical Practice Inspectors Working Group 2016

Transcription:

Standard operating procedure Title: Evaluation procedure for applications and requests for the establishment or review of Maximum Residue Limits (MRLs) Status: PUBLIC Document no.: SOP/V/4150 Lead author Approver Effective date: 05-MAY-17 Name: Sylvia Jahromy Name: Isaura Duarte Review date: 05-MAY-20 Signature: on file Signature: on file Supersedes: SOP/V/4051 (15-AUG-15) SOP/V/4052 (01-DEC-15) SOP/V/4053 (01-DEC-15) Date: 27-APR-17 Date: 27-APR-17 TrackWise record no.: 5228 1. Purpose This SOP serves to describe the procedure for the establishment or review of maximum residue limits (MRLs) incl. re-examination, where applicable. It does not describe the processing of requests for inclusion of a substance in the so-called out of scope list. 2. Scope This SOP applies to the appointed procedure teams for the establishment or review of MRLs, within the Veterinary Medicines Division. This SOP relates to standard and accelerated procedures for the establishment or review of MRLs under the following articles of Regulation (EC) 470/2009: applications under Article 3; requests under Article 9; applications for new substances included in biocidal products under Article 10; review requests under Article 11; accelerated procedures under Article 15; and requests for extrapolation under Article 27. 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.

The timelines of the accelerated procedures are stated in brackets after the timelines for the standard procedures, e. g. 120 (90) days. This SOP includes also the procedure for the re-examination of CVMP opinions on applications submitted to the Agency under Articles 3, 10 and 15 of Regulation (EC) 470/2009. 3. Responsibilities It is the responsibility of the Head of the Veterinary Medicines Department (delegated to the relevant Head of Service) to ensure that this procedure is adhered to within their own Department/Service. The responsibility for the execution of a particular part of this procedure is identified in the right-hand column of section 9. 4. Changes since last revision New SOP. New SOP/WIN structure implemented in the Division; this SOP implements the revised procedures for MRLs and includes the previously separate SOPs on Article 11 and Article 27 procedures into one main SOP for all MRL procedures. 5. Documents needed for this SOP Procedure templates in SIAMED (without pre-submission) Pre-submission templates in X:\Templates\Others\Vet\MRLs Procedure checklist in DREAM (EMA/153767/2017) 6. Related documents Regulation (EC) 470/2009 of the European Parliament and of the Council of 6 May 2009, laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) 2377/90 and amending Directive 2001/82/EC and Regulation (EC) 726/2004 of the European Parliament and of the Council Volume 8 tice to Applicants and te for Guidance: Establishment of maximum residue limits (MRLs) for residues of veterinary medicinal products in foodstuffs of animal origin Pre-submission guidance for MRL applications (http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_00028 3.jsp&mid=WC0b01ac058002da5e) List of recommended submission dates (published annually on the Agency website under http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listi ng_000165.jsp&mid=wc0b01ac058002d89b) SOP/PDM/1004 on Core Master Files of medicinal products for human and veterinary use following the centralised procedure SOP/V/4150 05-MAY-17 Page 2/15

7. Definitions AA APH Applicant EU-RL Checklist cmf CV CVMP EPMAR DREAM EFTA HDep HSer LoOI LoQ MRL MRL application Peer reviewer Administrative Assistant (here: assigned to vet.applications team) Animal and Public Health service (in the Veterinary Medicines department) A person submitting an application for the establishment of maximum residue limits under Article 3, 10 or 15 of Regulation (EC). 470/2009. For the purpose of this SOP the term applicant also refers to Member States or the European Commission when submitting a request to the Agency for the establishment or review of MRLs under Article 9, 11 or 27 of Regulation (EC). 470/2009. European Union Reference Laboratory Agency-internal document describing all administrative steps involved in a specific procedure. In this case refers to checklist on MRL procedures, unless otherwise specified. Core Master File Curriculum Vitae Committee for Medicinal Products for Veterinary Use European Public MRL Assessment Report Document Records Electronic Archive Management European Free Trade Association Head of Department (here: Head of Veterinary Medicines department) Head of Service (here: Head of VROS or Head of APH) List of outstanding issues List of questions Maximum residue limit Application for the establishment of maximum residue limits Procedure Coordinator, typically an Assistant, assigned to the management of the procedure CVMP member and/or alternate (who is not acting as rapporteur or co-rapporteur in the procedure) tasked with quality assurance of CVMP documents (in this case related to the establishment of maximum residue limits) (Co-)Rapporteur CVMP member and/or alternate appointed for the assessment of the application SIAMED S/CL SOP VMP Product information and application tracking system of the Agency Scientific administrator assigned as the scientific/content lead for the procedure Standard operating procedure; Agency document describing steps involved in a specific procedure Veterinary medicinal product SOP/V/4150 05-MAY-17 Page 3/15

VO VROS WIN Validating Officer, responsible for the validation of the application dossier (here: Administrative Assistant in VROS) Veterinary Regulatory and Organisational Support service (in the Veterinary Medicines department) Work Instructions SOP/V/4150 05-MAY-17 Page 4/15

8. Process map(s)/ flow chart(s) Start Art. 11 or 27? Pre-submission phase 1.1 Process notification of intent according to checklist. 1.2 tify applicant on rapporteur(s). 1.3 Confirm submission date with applicant. Submission 2.1 Process application/ request according to checklist. 2.4 Perform administrative validation. 2.5 tify applicant and rapporteur(s) of outcome. Art. 11* or 27? 2.3 tify applicant on rapporteur(s). Validation positive? Evaluation phase (next page) End * Except where the review is requested by the original applicant SOP/V/4150 05-MAY-17 Page 5/15

Evaluation phase 3.1 tify applicant of clock start. 3.2 Send assessment templates to rapporteur. 3.3 Initial evaluation according to checklist 3.4 Send rapporteurs assessment report to applicant 3.5 Monitor receipt of revised assessment & LoQ, if applicable 3.16 Finalisation of assessment and adoption of opinion. CVMP recommends MRL? 3.17 Send opinion to applicant. 3.7 CLOCK STOP Send LoQ to applicant. Art. 11 or 27? 3.8 Send updated assessment report to rapporteur. Re-examination? Re-examination request (next page) Go to 6.2 (next page) 3.9 Confirm submission date with applicant. 3.10 CLOCK START Receipt of responses to LoQ. 3.11 Evaluation of responses to LoQ (checklist). 3.15 Process LoOI according to checklist. 3.12 Send joint assessment to applicant. 3.14 Send list of outstanding issues to applicant. Oral explanations? SOP/V/4150 05-MAY-17 Page 6/15

Request for reexamination Within 15 days? 4.3 Submit for discussion at next CVMP meeting. 4.2 Inform applicant that cannot be accepted. 4.4 Inform Commission and EFTA. 4.5 Inform applicant on rapporteur(s) and oral explanation. Grounds within 60 days? Re-examination Post opinion 5.1 Send templates to rapporteur(s). 6.1 Inform applicant on CVMP conclusions. 5.2 Monitor timely receipt of assessment. 6.2 Send final opinion to Commission and EFTA. 5.4 Ensure timely receipt of presentation/cvs. Oral explanations? 6.3 Ensure cmf is complete. 5.5 Review and submit assessment to CVMP for adoption. 6.4 Publish EPMAR. End SOP/V/4150 05-MAY-17 Page 7/15

9. Procedure Step Action Responsibility 0.0 Is the procedure a request under Art. 11 or Art. 27 of Regulation (EC) 470/2009? If yes, go to 2.0 If no, go to 1.0. 1.0 Pre-submission phase 1.1 tification of intention to submit an MRL application is usually received 3 months before the intended submission 1. Upon receipt of letter of intent the notification is processed following the procedural steps described in the checklist. 1.2 Appointment of rapporteur and co-rapporteur, if applicable, as well as peer reviewers by CVMP: tify the applicant of the appointed rapporteur and co-rapporteur, if applicable, and of the recommended submission date(s). 1.3 Approx. 1 month before intended submission: Confirm submission date with applicant; amend recommended submission dates & inform rapporteur(s), if applicable. 2.0 Submission and validation of the MRL application 2.1 Upon receipt the MRL application or request is processed following AA the procedural steps described in the checklist. 2.2 Is the procedure a request under Art. 11 or Art. 27 of Regulation (EC) 470/2009? If yes, go to 2.3 2 If no, go to 2.4 2.3 Appointment of rapporteur, co-rapporteur, and peer reviewers, as applicable, by CVMP: tify the applicant of the appointed rapporteur and co-rapporteur, as applicable. Proceed to 3.0 2.4 Within 13 working days: Carry out administrative validation. VO 2.5 tify applicant, rapporteur and co-rapporteur of the outcome of VO the validation of the application. 2.6 Was the validation positive? If yes, go to 3.0 If no, proceed to 7.0 (end of procedure) 3.0 210 (120) 3 day Evaluation Phase 3.1 tify applicant of clock start: day 1. If applicable, notify relevant EU-RL of the start of the evaluation procedure. 3.2 Send the assessment report and scientific overview including list of questions templates to the rapporteur. 1 An MRL application shall be submitted at least 6 months before the application for the concerned marketing authorisation for the VMP. 2 Except where the review is requested by the original applicant 3 The number of days in brackets refers to the timeline for an accelerated procedure in accordance with Art. 15 of Regulation (EC) 470/2009 SOP/V/4150 05-MAY-17 Page 8/15

Step Action Responsibility 3.3 Initial evaluation within 120 (90) days following procedural steps described in checklist. Monitor timely receipt of: draft assessment report and scientific overview including list of questions, if applicable, from rapporteur critique of rapporteur s assessment report from the corapporteur, if applicable comments on assessment report from the peer reviewers, CVMP members and EU-RL, as applicable. 3.4 Send rapporteur s assessment report (incl. co-rapporteur s critique, if applicable) to applicant. 3.5 Monitor receipt of revised scientific overview including list of questions, if applicable, from the rapporteur. 3.6 Conclusion on initial evaluation and adoption of the scientific overview, if applicable, by CVMP (Day 120 (90)). Can the CVMP make a recommendation for the establishment of MRLs? If yes, go to 3.16 If no, go to 3.7 3.7 Clock Stop Send scientific overview with LoQ to applicant 4. If applicable, inform EU-RL on CVMP conclusions with regard to the analytical method. 3.8 Update rapporteur s assessment report in order to include the relevant comments from co-rapporteur, peer reviewers and other CVMP members in line with conclusions at day 120 (90). Send updated assessment report to rapporteur and co-rapporteur, if applicable, for agreement. 3.9 Confirm the exact submission date for responses to the LoQ with the applicant 2 months prior to the deadline. 3.10 Once the response 5 has been received on the agreed date according to submission dates, restart clock of the remaining evaluation period for days 121-210 (91-120) as described in checklist. If the scientific overview included questions on the analytical method inform EU-RL on the submission of the response to the LoQ and forward them to the EU-RL. 3.11 Evaluation of responses to list of questions within the remaining 90 (30) days following procedural steps described in checklist. Monitor timely receipt of: updated joint assessment report with assessment of responses to LoQ from rapporteur comments on assessment report from the peer reviewers, CVMP members and EU-RL, as applicable. 3.12 Send joint assessment report to applicant. S/CL 4 The Agency identifies an approximate submission date in the cover letter to the status report and LoQ; in general 6 months are granted to respond to the LoQ. This timeframe may be extended only exceptionally upon request and if duly justified. 5 One consolidated response to all questions should be submitted SOP/V/4150 05-MAY-17 Page 9/15

Step Action Responsibility 3.13 Has CVMP agreed to request or grant an oral explanation (and when to hear it) (Day 180/accelerated Day 120)? If yes, go to 3.14 If no, go to 3.16 3.14 Clock stop Send list of outstanding issues to applicant, if applicable. Process according to steps described in checklist. 3.15 Monitor timely receipt of revised rapporteurs assessment report following oral explanation from the rapporteur. Finalise assessment report and opinion including EPMAR for adoption by CVMP according to steps described in checklist, including relevant steps relating to legal scrutiny of the documents. 3.16 Monitor finalisation of assessment report and adoption of opinion including EPMAR for recommendation of MRL(s) at day 210(120). NB: If there is no LoQ at day 120(90), the opinion will be adopted at day 150(120). 3.17 Send opinion including EPMAR and CVMP assessment report to applicant, European Commission and EFTA according to procedural steps described in the checklist. 3.18 Is the procedure a request under Art. 11 or Art. 27 of Regulation (EC) 470/2009? If yes, go to 6.2 If no, go to 3.19 3.19 Did the applicant request a re-examination 6? If yes, go to 4.0 If no, go to 6.2 4.0 Receipt of a notification to request re-examination of CVMP opinion by the applicant 4.1 Was the notification received within the 15 day deadline? If yes, go to 4.3 If no, go to 4.2 4.2 Inform applicant that re-examination request cannot be accepted as deadline has passed. Go to 6.2 4.3 Inform applicant of submission of notification to CVMP, including notification of deadline for submission of detailed grounds for reexamination (see Annex IV). Submit notification for discussion (and decision on oral explanation, if requested by applicant) and appointment of rapporteur (and corapporteur, if appropriate) at next CVMP meeting. 4.4 Inform European Commission (and EFTA authorities) of receipt of notification to request re-examination. 4.5 Within 5 days after CVMP meeting: Inform applicant on rapporteur(s) for the re-examination and of decision on oral explanations, if applicable. 4.6 Were the detailed grounds received within the 60 day deadline? If yes, go to 5.0 If no, go to 4.2 S/CL 6 Within 15 days of receipt of the opinion, the applicant may provide written notice to the Agency secretariat of his intention to request re-examination of the recommendation (see Annex IV) SOP/V/4150 05-MAY-17 Page 10/15

Step Action Responsibility 5.0 Re-examination of CVMP opinion 5.1 Send the template for the assessment of the grounds for reexamination and EPMAR (previously adopted) in electronic format to the rapporteur for the assessment of the re-examination, to facilitate the inclusion of changes to the EPMAR. Submit detailed grounds for discussion at next CVMP meeting (first meeting after receipt of detailed grounds). 5.2 Monitor timely receipt of report on assessment of detailed grounds for re-examination as well as revised version of EPMAR from rapporteur. 5.3 Following initial discussion at CVMP meeting: Has CVMP agreed to grant an oral explanation (and when to hear it)? If yes, go to 5.4 If no, go to 5.5 5.4 If not already done earlier in the procedure, inform applicant of date and timing of oral explanation. At least 1 week before the CVMP meeting: Monitor timely receipt of presentation and CVs of applicant representatives. 5.5 At least 6 working days before the CVMP: review draft revised assessment report, draft final opinion (incl. revised EPMAR) for adoption by CVMP. Proceed to 6.0 6.0 Post Opinion 6.1 On the last day of CVMP meeting: finalise letter to applicant informing on the CVMP conclusions. Finalise CVMP opinion (incl. revised EPMAR) and CVMP assessment report. Send letter with opinion and assessment report to applicant via Eudralink. 6.2 On the following day after the end of the CVMP meeting (usually Friday) send final opinion including revised EPMAR to the European Commission and EFTA authorities, following the steps in checklist. 6.3 Check the completeness of the electronic cmf. Declare documents as a record in DREAM for the electronic cmf, if not done previously. 6.4 Did the CVMP recommend provisional MRLs for the substance? If yes, go to 3.9 If no, go to 6.5 6.5 Within 10 days following publication of the relevant EC Regulation in the Official Journal: Arrange for publication of EPMAR on Agency website. Proceed to 7.0 7.0 End of procedure S/CL 10. Records Electronic copies are saved in the appropriately labelled folder in DREAM. SOP/V/4150 05-MAY-17 Page 11/15

Annex I Submission of MRL application dossiers to CVMP (published as a separate document) (http://www.ema.europa.eu/docs/en_gb/document_library/regulatory_and_procedural_guideline/200 9/11/WC500014483.pdf) As of 1 January 2017 it is mandatory for applicants to use the esubmission Gateway/Web Client for all veterinary procedural submissions to the Agency. For more information, including links to guidance on registration with the system, refer to the Veterinary e-submission website: http://esubmission.ema.europa.eu/tiges/vetesub.htm. SOP/V/4150 05-MAY-17 Page 12/15

Annex II Standard timetable for evaluation of MRL applications Pre-submission phase Day Step -180 to -90 tification of intent to submit an application for the establishment of MRLs -180 to -60 CVMP plenary meeting following receipt of letter of intent Appointment of rapporteur(s) and peer reviewer; notification of recommended submission dates to applicant -14 Submission of application dossier 0 Validation Evaluation Day Step +1 Start of assessment procedure +70 Rapporteurs assessment report +120 CVMP decision on the need for further information with the adoption of a scientific overview including a list of questions +150 Opinion, if no further information required If further information is required: Clock stop - 6 months timeline for submission of responses +121 Submission of written responses by the applicant (clock re-start) +160 Rapporteurs updated assessment report with assessment of responses to the list of questions including rapporteurs views on need for oral or written explanations; applicant may (also) request to provide oral explanations to CVMP +180 CVMP discussion of draft opinion or CVMP request for oral or written explanations on outstanding issues 7 CVMP may agree a 1-2 month clock stop to allow for preparation of oral or written explanations, if justified. Clock stop +181 Oral explanation (as appropriate) (clock re-start) +210 CVMP opinion 7 Oral explanations can also be granted at the request of the applicant SOP/V/4150 05-MAY-17 Page 13/15

Annex III Timetable for accelerated evaluation of MRL applications Pre-submission phase Day Step -180 to -90 tification of intent to submit an application for the establishment of MRLs, including notification of intention to submit a request for accelerated assessment -180 to -60 CVMP plenary meeting following receipt of letter of intent Appointment of rapporteur(s) and peer reviewer; discuss request for accelerated procedure; if necessary request rapporteur(s) to further consider the request and advise the Committee; notification of recommended submission dates to applicant -90 to 0 If not decided at a previous meeting, consider advice from rapporteur(s) and decide on accelerated procedure; communication of conclusions to applicant -14 Submission of application dossier 0 Validation of dossier Initial evaluation Day Step +1 Start of assessment procedure +45 Rapporteurs assessment report +90 CVMP opinion or CVMP expresses the need for further information (list of questions); in the latter case: Clock stop - 6 months timeline for submission of responses 8 +91 Submission of written responses by the applicant (clock re-start) +115 Rapporteurs joint assessment report including rapporteurs views on need for oral or written explanations; applicant may request to provide oral explanations to CVMP +119 CVMP discussion of draft opinion or CVMP request for oral or written explanations CVMP may agree a 1-2 month clock stop to allow for preparation of oral or written explanations, if justified. +120 Oral explanation (as appropriate) and opinion 8 Depending on the extent of the list of questions and the amount of data expected the CVMP might decide to revert the assessment to a standard timetable, i. e. evaluation of the responses to the list of questions in 90 days instead of 30 days. SOP/V/4150 05-MAY-17 Page 14/15

Annex IV Presentation of detailed grounds for request for re-examination Requests for re-examination and supporting grounds shall contain argumentation and clarification of data previously submitted in the original application. It is not considered the purpose of a reexamination to provide an opportunity for the submission of new data. The detailed grounds for re-examination shall be presented in one of the following ways: a. Attached to the written notice by the applicant to the Agency secretariat of his intention to request the re-examination of the CVMP opinion (send within 15 days after receipt of the CVMP opinion). b. Submitted separately from the written notice within 60 days of receipt of the CVMP opinion to the Agency secretariat and to CVMP members and alternates taking into account the dossier submission requirements in Annex I (addresses as per CVMP member list: http://www.ema.europa.eu/htms/general/contacts/cvmp/cvmp_members.html). The day of the receipt is the day when the applicant receives the opinion by Eudralink. Days are counted as calendar days. The period starts at the day following the receipt of the opinion. Where the last day in a specific period falls on a Saturday, Sunday or Public Holiday the following working day will be considered as the final day. Applicants are advised to contact the Agency secretariat before submitting the grounds for reexamination to discuss submission date and to clarify the most suitable option. Timeline for re-examination procedure Day 0 15 after receipt of CVMP opinion by Eudralink: Next CVMP meeting: Day 0 60 after receipt of CVMP opinion by Eudralink: First CVMP meeting after receipt of grounds: Second CVMP meeting after receipt of grounds: Applicant sends notification of request for re-examination Appointment of (co-) rapporteur for reexamination procedure Applicant sends detailed grounds for reexamination of CVMP opinion Initial discussion at CVMP, agreement on need/granting of oral explanations Oral explanations (if applicable) Adoption of final (revised or unchanged) CVMP opinion SOP/V/4150 05-MAY-17 Page 15/15